ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMGastos comerciales, generales y administrativos2.86 B2.55 B2.65 B2.63 B2.9 B2.7 B10.88 BInvestigación y desarrollo4.58 B3.62 B4.05 B4.23 B3.89 B12.59 B24.76 BBeneficio operativo1.64 B5.87 B4.99 B6.51 B375 M-3.4 B8.48 BTotal de ingresos no operativos123 M202 M150 M430 M-298 M-7 M275 MGastos por intereses, netos de intereses capitalizados328 M313 M305 M327 M412 M479 M1.52 BIngresos no operativos, una vez deducidos los gastos por intereses-76 M-146 M-162 M-135 M-279 M-348 M-924 MIngresos/gastos extraordinarios-129 M35 M7 M238 M-431 M-138 M-324 MBeneficio antes de impuestos4.17 B5.9 B5 B6.75 B3.42 B-3.53 B11.63 BParticipación en los beneficios———————Impuestos426 M818 M571 M958 M457 M709 M2.69 BParticipación minoritaria1 M6 M1 M2 M0-3 M0Otros ingresos/gastos después de impuestos101 M-109 M-335 M51 M-118 M-20 M-422 MBeneficio neto antes de actividades interrumpidas3.74 B5.08 B4.43 B5.79 B2.96 B-4.24 B8.94 BOperaciones suspendidas———————Beneficio neto3.74 B5.08 B4.43 B5.79 B2.96 B-4.24 B8.94 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas3.74 B5.08 B4.43 B5.79 B2.96 B-4.24 B8.94 BBeneficio básico por acción1.482.011.762.321.21-1.723.57Beneficio por acción diluido1.492.011.762.321.19-1.723.55Número medio de acciones ordinarias2.53 B2.52 B2.51 B2.5 B2.5 B2.47 B—Acciones diluidas2.54 B2.53 B2.51 B2.5 B2.51 B2.47 B—EBITDA2.84 B6.97 B6.11 B7.66 B2.84 B-1.88 B14.73 BEBIT1.64 B5.87 B4.99 B6.51 B375 M-3.4 B8.48 BCosto de los ingresos3.83 B3.42 B3.56 B3.85 B5.55 B4.2 B17.16 BOtros costes de producción———————Amortización y depreciación (flujo de caja)1.2 B1.1 B1.12 B1.15 B2.47 B1.51 B6.25 B
Merck & Company, Inc. Common Stock
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue.
The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products.
The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000.
In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck".